Skip to main content
Clinical Trials/NCT01832168
NCT01832168
Completed
Not Applicable

A Prospective Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy (RALP)- Effect on Nerve Protection.

MiMedx Group, Inc.1 site in 1 country34 target enrollmentFebruary 2013
ConditionsPudendal Nerve

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pudendal Nerve
Sponsor
MiMedx Group, Inc.
Enrollment
34
Locations
1
Primary Endpoint
The proportion of patients achieving return to baseline Sexual Health Inventory for Men (SHIM) score in the AmnioFix group versus the Control group.
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of this study is to determine whether the AmnioFix dehydrated human amniotic membrane is effective in protecting nerves in men receiving robotic assisted laparoscopic prostatectomies.

Registry
clinicaltrials.gov
Start Date
February 2013
End Date
June 2014
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Clinically localized prostate cancer with Gleason score 6 or 7
  • SHIM Score greater than or equal to 16 in the absence of medication
  • Feasibility to perform unilateral or bilateral nerve sparing RALP

Exclusion Criteria

  • Clinically locally advanced cancer and/or with Gleason score 8 or
  • Difficulty performing nerve sparing RALP.
  • Prior surgery at the site.
  • Site exhibits clinical signs and symptoms of infection.
  • SHIM score at screening \<
  • Current use of anticoagulant medication including Coumadin, Plavix, etc.
  • Has had "salvage prostatectomy" - patients who failed prior therapies including external radiation therapy, cryotherapy, etc.
  • Has prior radiation therapy treatment at the site.
  • Prior hormonal therapy such as Lupron or oral anti-androgens.
  • Non-mobile, i.e. not ambulatory or bed ridden.

Outcomes

Primary Outcomes

The proportion of patients achieving return to baseline Sexual Health Inventory for Men (SHIM) score in the AmnioFix group versus the Control group.

Time Frame: 4 weeks

Secondary Outcomes

  • Time to return of erectile function.(Up to 6 months)
  • Pain scores.(10 days, 4 weeks, 3 months, and 6 months)

Study Sites (1)

Loading locations...

Similar Trials